Series A · circadian performance systems V3LA One — clinical validation underway
Press kit

Everything you need to write about us.

Boilerplate, assets, and the claims we will and won't stand behind. For interviews, contact press — we usually reply the same day.

Boilerplate

V3LA builds circadian performance systems for people whose schedules don't match their biology. Its first product pairs a minimal titanium sensor — continuous distal temperature and motion, nine-day battery, no screen — with software that estimates the wearer's internal clock and turns that estimate into daily decisions about sleep, light and caffeine timing.

Founded in 2025 by a healthcare worker building the product on their own night rotation, V3LA is a remote-first company serving shift workers, clinicians and anyone on an irregular schedule. V3LA One is a general wellness product and not a medical device.

Fast facts

Founded2025
Headcount15
Funding$6.4M Series A
First productV3LA One, Q1 2027
Price$249 + $12/mo
Pilot participants1,900

Assets

V3LA logo
Primary logo — PNG, SVGRequest
Available on request
Product photographyRequest
App screen capturesRequest
Founder and team portraitsRequest
Validation charts, print qualityRequest

Tell us your deadline and we'll send a folder the same day.

Brand basics
Written formV3LA
PronouncedVAY-la
NeverVela, V3la, V-3-LA
DescriptorWearables · research

Assets may be used in editorial coverage of V3LA without further permission. Please don't alter the logo, recolour product shots, or composite the ring onto other devices.

Claims we stand behind — and don't

Accurate
  • Estimates circadian phase from distal temperature and motion
  • ±19 min median error against lab DLMO in a 68-participant pilot
  • Nine-day battery, no charging during a shift block
  • Runs inference on-device by default
Please avoid
  • "Treats shift work sleep disorder" — not cleared for any indication
  • "Medical device" or "FDA approved"
  • "Cures fatigue" or any performance guarantee
  • Describing pilot figures as clinical trial results